Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:59:03.691Z.
Calculation as of: 2026-10-06T19:59:03.691Z.
Quote observation: 2026-10-06T19:55:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c51f7bb38e0467dbdaec2b87e904118633479c78190bb705d814f7e841715b6d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
SELLAS Life Sciences Group, Inc.
Market Cap
$2.11B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.11B
EBITDA Yield
7.78%
TTM Avg
7.38%
3Y Avg
6.36%
5Y Avg
5.86%
Market Cap
$2.06B
EBITDA Yield
N/A
TTM Avg
1.31%
3Y Avg
2.16%
5Y Avg
2.16%
Market Cap
$2.16B
EBITDA Yield
6.68%
TTM Avg
11.96%
3Y Avg
10.61%
5Y Avg
16.98%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | $2.11B | N/A | N/A | N/A | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.78% | 7.38% | 6.36% | 5.86% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.10B | N/A | N/A | N/A | N/A |
| GeneDx Holdings Corp. (WGS)vs › | $2.14B | N/A | 0.73% | 0.73% | 0.73% |
| Alvotech (ALVO)vs › | $2.08B | 2.38% | 3.21% | 2.55% | 2.55% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.07B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 1.31% | 2.16% | 2.16% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.16B | 6.68% | 11.96% | 10.61% | 16.98% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | N/A | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 1.53% | 1.16% | 0.60% | 0.56% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
